This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Falagas ME, Rafailidis PI (2008) Re-emergence of colistin in today’s world of multidrug-resistant organisms: personal perspectives. Expert Opin Investig Drugs 17:973–981
Karaiskos I, Giamarellou H (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15:1351–1370
Kumarasamy KK, Toleman MA, Walsh TR et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602
Bergen PJ, Landersdorfer CB, Zhang J et al (2012) Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis 74:213–223
Gilbert B, Morrison C (2017) Evaluation of intraventricular colistin utilization: a case series. J Crit Care 40:161–163
Landersdorfer CB, Nation RL (2015) Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med 36:126–135
Grégoire N, Aranzana-Climent V, Magréault S, Marchand S, Couet W (2017) Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet 56:1441–1460
Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436
Nation RL, Garonzik SM, Thamlikitkul V et al (2017) Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis 64:565–571
Leypoldt JK, Jaber BL, Lysaght MJ, McCarthy JT, Moran J (2003) Kinetics and dosing predictions for daily haemofiltration. Nephrol Dial Transplant 18:769–776
Jeffrey RF, Khan AA, Prabhu P et al (1994) A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system. Artif Organs 18:425–428
Elbers PW, Girbes A, Malbrain ML, Bosman R (2015) Right dose, right now: using big data to optimize antibiotic dosing in the critically ill. Anaesthesiol Intensive Ther 47:457–463
Martinkova J, Malbrain ML, Havel E, Šafránek P, Bezouška J, Kaška M (2016) A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam. Anaesthesiol Intensive Ther 48:23–28
Azad MA, Huang JX, Cooper MA et al (2012) Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein. Biochem Pharmacol 84:278–291
Dudhani RV, Li J, Nation RL (2009) Plasma binding of colistin involves multiple proteins and is concentration dependent: potential clinical implications. Abstracts of the forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, p 41
Herve F, Gomas E, Duche JC, Tillement JP (1993) Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol 36:241–249
Israili ZH, Dayton PG (2001) Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 33:161–235
Pea F, Viale P, Pavan F, Furlanut M (2007) Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 46:997–1038
Mariano F, Leporati M, Carignano P, Stella M, Vincenti M, Biancone L (2015) Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol 28:623–631
Honore PM, Jacobs R, Lochy S et al (2013) Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis 6:107–111
Honore PM, Jacobs R, Joannes-Boyau O et al (2013) Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J 59:99–106
Karaiskos I, Friberg LE, Galani L et al (2016) Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 48:337–341
Verdoodt A, Honore PM, Jacobs R, Van Gorp V, Hubloue I, Spapen HD (2017) High-dose colistin combined with continuous veno-venous haemofiltration for treatment of multidrug-resistant Gram-negative infection in critically ill patients. Intensive Care Med Exp 5(Suppl 2):44-0986 (abst)
Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC (2010) Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 54:1941–1948
Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD (2015) Higher colistin dose during continuous renal replacement therapy: look before leaping! Crit Care 19:235
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Honore, P.M., Malbrain, M.L.N.G., Spapen, H.D. (2018). Colistin Dosing in Continuous Renal Replacement Therapy. In: Vincent, JL. (eds) Annual Update in Intensive Care and Emergency Medicine 2018. Annual Update in Intensive Care and Emergency Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-73670-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-73670-9_6
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73669-3
Online ISBN: 978-3-319-73670-9
eBook Packages: MedicineMedicine (R0)